The new blood test offers an inexpensive and minimally invasive biomarker-based method to screen and identify patients early, easily and accurately that contributes to improved quality of life.
Mission of ToxGenSolutions
Opportunity for business development in a massive market
Definition of the problem
What is expected?
ToxGenSolutions can offer the solution to the problem:
Market Focus: A market that is discouraged and frustrated.
ToxGenSolutions acquired funding ($400,000) from EU Interreg. Vlaanderen-Nederland to evaluate a prototype diagnostics for early Alzheimer'sJanuary, 2018
3Rs Management and Consulting ApS (Lyngby, Denmark), co-owner of ToxGenSolutions (34%) provides a loan of $32,800 to secure IP rights.January, 2017
ToxGenSolutions acquired a $107,500 pre-seed loan from UNIVENTURE (Maastricht, Netherlands) to establish the feasibility of the business.November, 2015
ToxGenSolutions BV was established at Oxfordlaan 70, 6229 EV Maastricht, the Netherlands.May, 2015
Yes. The lack of accurate diagnostic methods and active drugs, despite decades of research into the causes and underlying processes of Alzheimer's, has led to disappointed and frustrated patients and caretakers. Due to the lack of success, Pharma and Biotech companies have temporary stopped further research and development of new drugs. Causes of failure are several: (1) animal models do not develop human pathology and have little relevance human health, (2) research focus has been on disease stages with irreversible brain damage, and (3) animal models represent genetic Alzheimer's which represents <5% of the Alzheimer’s cases. Thus, there is a need for a new approach making research, and the emerging tools and drugs, more relevant for human health.
Yes. Patients, caretakers and drug developers require more accuracy, early diagnosis, inexpensive and minimally invasive methods and biomarker profiles. 1. Low accuracy: The current strategy for diagnosing Alzheimer's appears to have an accuracy of <50%, despite it concerns patients with memory disorders and thus clear brain damage. This should be >90%. 2. Early diagnosis: The late and inaccurate diagnosis is considered the reason for the high failure rate (> 99%) during drug development and the absence of options to improve the quality of life of patients and their families. 3. Costs and invasiveness: There is an urgent need for inexpensive and minimally invasive testing to more easily and accurately screen and identify patients in the earliest stages of the disease before irreversible injury and associated symptoms occur. 4. Biomarkers: Clinical studies (e.g. cancer) are twice as likely to be successful if patients are selected using validated biomarkers. This strategy must be applied to Alzheimer's.
ToxGenSolutions offers an inexpensive and minimally invasive biomarker-based method to screen and identify patients more easily and accurately in the earliest stages of the disease. This approach has benefits for patients, caregivers, the community and drug developers: (1) Better quality of life: Early diagnosis gives the patient the opportunity to change his lifestyle in time, and to participate in training programs that slow the development of the disease; (2) Faster certainty about treatment: An early and accurate biomarker-based diagnosis gives the doctors and caregivers certainty in an early phase of the disease about the treatment; (3) Lower costs for health care: An inexpensive method that allows minimally invasive, rapid and accurate screening increases the chance that cheaper treatment strategies; (4) New possibilities for the development of active drugs: The test identifies non-genetic Alzheimer's patients (>95% of total) before brain injuries occur and facilitates effective drug development.